Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ultragenyx (NASDAQ: RARE) reported an inducement grant of 10,839 restricted stock units to two newly hired non-executive officers under the Ultragenyx Employment Inducement Plan, with a grant date of March 16, 2026.

The awards were approved by the compensation committee and vest over four years, with 25% of underlying shares vesting on each anniversary, subject to continued employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – RARE

+2.01%

4 alerts

+2.01% Session close to close

+4.8% Peak Tracked

$1.97B Market Cap

9.23K Volume

In the Mar 23 session, RARE gained 2.01%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.8% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a standard equity-based hiring incentive: 10,839 restricted stock units gr...

Analysis

This announcement details a standard equity-based hiring incentive: 10,839 restricted stock units granted to two new non-executive officers under an inducement plan, vesting over 4 years at 25% annually. It adds to an active backdrop that includes recent Phase 3 DTX301 data and a Priority Review BLA for DTX401. Investors may watch how ongoing insider stock activity and future clinical milestones interact with a share price trading well below the $29.73 200-day moving average.

Key Figures

RSU grant size: 10,839 restricted stock units Number of employees: 2 employees Vesting schedule: 25% per year +1 more

4 metrics

RSU grant size 10,839 restricted stock units Employment Inducement Plan grant to two new non-executive officers

Number of employees 2 employees Newly hired non-executive officers receiving inducement RSUs

Vesting schedule 25% per year RSUs vest in four equal annual installments

Vesting term 4 years Full vesting over four years from March 16, 2026 grant date

Historical Context

5 past events · Latest: Mar 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 12	Phase 3 data	Positive	-2.3%	Positive 36-week Phase 3 DTX301 OTC data with ammonia reduction benefits.
Feb 27	Legal action notice	Negative	-1.6%	Class action application deadline notice for Ultragenyx investors.
Feb 24	Legal action notice	Negative	+0.7%	Class action lawsuit update highlighting April 6, 2026 investor deadline.
Feb 23	Investor conferences	Positive	+1.1%	Participation in three March healthcare investor conferences with management.
Feb 23	Regulatory milestone	Positive	-0.9%	FDA acceptance and Priority Review of DTX401 BLA with set PDUFA date.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical and regulatory updates have often coincided with negative or muted next-day price moves, while legal headlines and conferences have shown mixed reactions.

Recent Company History

Over the last month, Ultragenyx has reported multiple material events. On Feb 23, the FDA accepted the BLA for DTX401 with Priority Review and a Aug 23, 2026 PDUFA date, yet shares fell 0.92%. Positive Phase 3 DTX301 data on Mar 12 was followed by a 2.25% decline. Legal class-action notices in late February produced small, mixed moves, while March investor conference participation saw a modest 1.07% gain. Today’s routine inducement grant fits into this backdrop of significant clinical progress alongside cautious trading.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), employment inducement plan

3 terms

restricted stock units financial

"reported the grant of 10,839 restricted stock units of the company’s common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

employment inducement plan financial

"granted under the Ultragenyx Employment Inducement Plan"

An employment inducement plan is a package of pay, bonuses or stock-based awards offered to a new hire to persuade them to join a company, similar to a signing bonus or welcome offer. Investors care because these awards can increase payroll costs and dilute existing shares, while also signaling how much the company is spending to attract talent and align that new hire’s interests with shareholder value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NOVATO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 10,839 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of March 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

What did Ultragenyx (RARE) announce about the inducement grant on March 20, 2026?

Ultragenyx announced a grant of 10,839 restricted stock units to two new non-executive officers. According to the company, the awards were approved by the compensation committee and granted under the Employment Inducement Plan with a March 16, 2026 grant date.

How do the restricted stock units granted by Ultragenyx (RARE) vest and over what timeline?

The restricted stock units vest over four years with 25% vesting each anniversary. According to the company, vesting is contingent on continuous employment as of each anniversary date following the March 16, 2026 grant.

Why was the Ultragenyx (RARE) equity award granted under Nasdaq Listing Rule 5635(c)(4)?

The award was an inducement material to hiring new employees under Nasdaq Rule 5635(c)(4). According to the company, the grant was intended as a recruitment inducement for two newly hired non-executive officers.

How many employees received restricted stock units in the Ultragenyx (RARE) March 2026 grant?

Two newly hired non-executive officers received the restricted stock units. According to the company, the total grant was 10,839 restricted stock units awarded under the Employment Inducement Plan.

Does the Ultragenyx (RARE) press release indicate any immediate cash impact from the inducement grant?

No immediate cash impact was disclosed; the grant is equity-based and vests over time. According to the company, the awards are restricted stock units that vest subject to continued employment rather than upfront cash payments.